Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation in stem-cell transplantation.

Reem A Abo-Zena1, Mitchell E Horwitz

  • 1Bone Marrow Transplant, National Institutes of Health, Pharmacy Department Building 10, Room 1N-257, Bethesda, Maryland 20892-1196, USA. rabozena@nih.gov

Current Opinion in Pharmacology
|July 20, 2002
PubMed
Summary

Graft-versus-host disease (GVHD) affects many stem-cell transplant patients. New treatments show promise for acute GVHD, but chronic GVHD remains challenging.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms.

Bone marrow transplantation·2026
Same author

Impact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment.

Bone marrow transplantation·2026
Same author

Single-centre analysis of prophylactic dexamethasone on the incidence and severity of cytokine release syndrome and immune effector cell-associated neurotoxicity in patients receiving axicabtagene ciloleucel.

British journal of haematology·2026
Same author

Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources.

Blood neoplasia·2026
Same author

Exploring Perspectives on Feasibility, Challenges, and Support Needs for Chlorhexidine Gluconate (CHG) Bathing in the Outpatient Setting for Hematopoietic Cell Transplant Recipients: A Qualitative Study.

Transplantation and cellular therapy·2025
Same author

Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program.

Transplantation and cellular therapy·2025

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Acute graft-versus-host disease (GVHD) affects 30-60% of allogeneic stem-cell transplant recipients.
  • Chronic GVHD impacts 35-50% of patients, posing a significant long-term challenge.
  • Steroids are a primary treatment, but refractory cases require alternative strategies.

Purpose of the Study:

  • To review current prophylaxis and treatment strategies for acute and chronic graft-versus-host disease.
  • To highlight recent advancements in managing steroid-refractory acute GVHD.
  • To discuss the ongoing challenges in treating chronic GVHD.

Main Methods:

  • Review of existing literature on GVHD prophylaxis and treatment.
  • Analysis of emerging therapies for acute and chronic GVHD.
  • Discussion of novel agents including monoclonal antibodies and TNF inhibitors.

Main Results:

  • Cyclosporine and methotrexate are standard prophylaxis, with tacrolimus and mycophenolate mofetil gaining traction.
  • Sirolimus shows potential but has limited published data.
  • Monoclonal antibodies (e.g., daclizumab) and TNF inhibitors (e.g., infliximab) offer promising results for steroid-refractory acute GVHD.

Conclusions:

  • While prophylaxis options evolve, managing steroid-refractory acute GVHD has seen significant therapeutic advances.
  • Effective treatments for chronic GVHD beyond steroids remain a critical area for ongoing research and development.

Related Experiment Videos